Previous 10 | Next 10 |
home / stock / anpcy / anpcy news
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay GUILDFORD, SURREY / ACCESSWIRE / March 22, 2024 / ANGLE plc (AIM:AG)(O...
REVIEW PAPER ON MOLECULAR ANALYSIS OF PARSORTIX CTC HARVEST HIGHLIGHTS POTENTIAL UTILITY IN PRECISION ONCOLOGY Paper published in the journal "Current Issues in Molecular Biology" special issue: advanced solutions for cancer therapy GUILDFORD, SURREY / ACCESSWIRE / January 22, 2024 / AN...
Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701 GUILDFORD, SURREY / ACCESSWIRE / January 2, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnosti...
USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY Harvested CTCs reveal gene expression profile associated with development and progression of brain metastasis in melanoma Researchers suggest such profiling could prove to be "pivotal" to prescribing m...
GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is pleased to announce that Berenberg will ...
ANGLE LAUNCHES PORTRAIT+ CTC KIT AT SAN ANTONIO BREAST CANCER SYMPOSIUM ANGLE's Portrait+ CTC staining kit combines the power of Parsortix ® technology with an optimised immunofluorescent assay The test is designed for highly accurate, repeatable, and precise results allowing ...
NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small-Cap Growth Virtual Investor Conference, held November 30 th are now available for online viewing. REGISTER NOW...
NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Small Cap Growth Virtual Investor Conference to be held on November 30 th , 2023. Individual investors, institutional investors, adv...
ANGLE LAUNCHES PD-L1 TEST TO SUPPORT CANCER THERAPY STUDIES ANGLE's Portrait PD-L1 test uses CTCs harvested from the Parsortix system to investigate real-time patient PD-L1 status for clinical studies The test is designed for highly accurate, repeatable, and precise results for CTC PD-L...
Revenue recognised for 2023 expected to be up 120% at c. £2.2 million with sales secured in 2023 expected to be c. £3.3 million Revenue recognised for 2024 expected to treble compared to 2023 Cash runway extended into Q2 2025 GUILDFORD, SURREY / ACCESSWIRE / November 9, 20...
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Surrey ADR Company Name:
ANPCY Stock Symbol:
OTCMKTS Market:
Angle Plc Surrey ADR Website:
GUILDFORD, SURREY / ACCESSWIRE / July 11, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that the audited Annual Report a...
PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT THE 2024 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH ANGLE presenting two posters highlighting the utility of CTC & ctDNA dual analysis and ANGLE's DNA Damage Response assay GUILDFORD, SURREY / ACCESSWIRE / June 11, ...